Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B and coccidioidomycosis.

Royce H Johnson1, Hans E Einstein

  • 1Kern Medical Center-Medicine, 1830 Flower Street, Bakersfield, CA 93305, USA. johnsonr@kernmedctr.com

Annals of the New York Academy of Sciences
|May 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic and transcriptomic determinants of disseminated coccidioidomycosis identify a founder variant in <i>NLRX1</i> and ancestry-specific rare variants in immune response genes.

medRxiv : the preprint server for health sciences·2026
Same author

Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions.

Journal of fungi (Basel, Switzerland)·2026
Same author

Exhausted T cell phenotypes in disseminated coccidioidomycosis.

JCI insight·2026
Same author

Th2 skewing in patients with disseminated coccidioidomycosis.

JCI insight·2026
Same author

Exhausted T cell phenotypes in disseminated coccidioidomycosis.

medRxiv : the preprint server for health sciences·2026
Same author

The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?

Journal of fungi (Basel, Switzerland)·2025

Amphotericin B was the primary treatment for coccidioidomycosis until azoles emerged. Lipid formulations of amphotericin B reduce toxicity, offering a safer alternative for severe fungal infections.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Coccidioidomycosis treatment lacked effective therapies before the 1950s.
  • Amphotericin B revolutionized coccidioidomycosis treatment, becoming the standard for severe cases.
  • Azoles and triazoles have since become primary treatments, shifting amphotericin B to rescue therapy.

Purpose of the Study:

  • To review the historical and current therapeutic landscape of coccidioidomycosis.
  • To highlight the evolving role of amphotericin B and its formulations.
  • To discuss the advantages of newer lipid-based amphotericin B preparations.

Main Methods:

  • Literature review of coccidioidomycosis treatment.
  • Historical analysis of antifungal drug development.

Related Experiment Videos

  • Comparative assessment of amphotericin B and azole therapies.

    • Main Results:

    • Amphotericin B remains crucial for severe, disseminated, or refractory coccidioidomycosis.
    • Lipid formulations of amphotericin B demonstrate reduced nephrotoxicity compared to conventional forms.
    • Intrathecal amphotericin B is still utilized for coccidioidal meningitis.

    Conclusions:

    • Amphotericin B, especially lipid formulations, remains a vital therapeutic option for coccidioidomycosis.
    • The choice of antifungal therapy depends on disease severity, patient factors, and drug tolerance.
    • Ongoing research into antifungal agents is essential for improving coccidioidomycosis management.